MRC/University Molecular Hepatology Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Hepatol Res. 2008 Jun;38(6):580-92. doi: 10.1111/j.1872-034X.2007.00315.x. Epub 2008 Jan 14.
Hepatitis B virus (HBV) e antigen (HBeAg) is translated from precore mRNA as a precore/core protein, which is post-translationally modified to give rise to the protein that is secreted into the serum. The G1862T mutation in HBV occurs in the bulge of the encapsidation signal within the pregenomic RNA. When the precore mRNA is translated, this mutation results in a valine to phenylalanine substitution at the -3 position to the signal peptide cleavage site at the amino end of the precursor protein. The aim of this study was to determine whether this mutation could affect HBV replication and/or HBeAg expression.
Following transfection of Huh 7 cells, HBV replication was followed using real time polymerase reaction (PCR) and expression of HBeAg expression was monitored using confocal microscopy.
HBV replication was reduced when this mutation was introduced into genotype D but not into genotype A replication-competent constructs. Using mutant HBeAg-expressing plasmids, we demonstrated a 54% reduction in HBeAg secretion relative to the wild type. Confocal microscopy demonstrated that the mutant HBeAg accumulated in the endoplasmic reticulum, endoplasmic reticulum intermediate compartment and Golgi. These aggregates of mutant protein increased in size following treatment of the cells with a proteasome inhibitor, MG132, and had the hallmark features of aggresomes. They attracted ubiquitin, heat shock proteins and proteasomes and were isolated from the cytosol by the intermediate filaments, vimentin and cytokeratin.
The formation of aggresomes, as a result of the G1862T mutation, may play a contributory role in HBV-induced liver disease.
乙型肝炎病毒 (HBV) e 抗原 (HBeAg) 由前核心 mRNA 翻译而来,作为前核心/核心蛋白,其在翻译后被修饰,产生分泌到血清中的蛋白。HBV 中的 G1862T 突变发生在前基因组 RNA 的包膜信号的凸起处。在前核心 mRNA 翻译时,该突变导致信号肽切割位点处前体蛋白氨基末端的 -3 位缬氨酸被苯丙氨酸取代。本研究旨在确定该突变是否会影响 HBV 复制和/或 HBeAg 表达。
在 Huh 7 细胞转染后,通过实时聚合酶反应 (PCR) 监测 HBV 复制,通过共聚焦显微镜监测 HBeAg 表达。
当该突变被引入基因型 D 但未被引入复制能力的基因型 A 构建体时,HBV 复制减少。使用突变 HBeAg 表达质粒,我们证明与野生型相比,HBeAg 分泌减少了 54%。共聚焦显微镜显示,突变 HBeAg 在内质网、内质网中间隔室和高尔基体中积累。在用蛋白酶体抑制剂 MG132 处理细胞后,这些突变蛋白的聚集体大小增加,并且具有聚集物的典型特征。它们吸引泛素、热休克蛋白和蛋白酶体,并通过中间丝、波形蛋白和细胞角蛋白从细胞质中分离出来。
由于 G1862T 突变形成聚集物,可能在 HBV 诱导的肝病中起作用。